Pyrilutamide (KX-826): The Topical AR Antagonist Nearing Approval in Asia

Most new hair loss drugs are developed in the US and Europe, so the West usually gets them first. Pyrilutamide is the exception. Developed in China, it has already cleared its pivotal Phase 3 trial there and is heading for approval in Asia, potentially years before Western markets. It also works through the same mechanism as clascoterone, setting up the first real race between two topical DHT blockers.

By Radiance360 · Pharmacist-Formulated · 2026

The quick answer

What is pyrilutamide? A topical androgen receptor antagonist (also called KX-826) that blocks DHT at the hair follicle without lowering DHT throughout the body. Developed by Kintor Pharmaceutical in China.

Does it work? In a 666-patient Phase 3 trial in China, the 1.0% twice-daily formulation increased hair count by 10.65 hairs per square centimetre more than placebo, meeting its primary endpoint.

Is it FDA approved? No. It is not approved by any regulator yet. Kintor is filing in China first, with no announced US or European filing.

When will it be available? Approval in China could come first, potentially around 2027. Western availability, if it happens, is years further out, and Pakistan later still.

What Pyrilutamide Is and How It Works

Pyrilutamide belongs to the same new drug class as clascoterone: the topical androgen receptor antagonist.

DHT damages hair follicles by binding to androgen receptors inside them, delivering the signal that shrinks genetically sensitive follicles. Pyrilutamide competes with DHT for those receptors, occupying them in the scalp so DHT cannot bind. The follicle is shielded locally, at the point of application.

The key feature, shared with clascoterone, is that this happens locally, not systemically. Finasteride lowers DHT across the whole body, effective but carrying a risk of hormonal side effects. Pyrilutamide does not reduce the body's DHT at all; it blocks the receptor where applied. That is the appeal of this drug class: interfering with DHT's effect on the scalp without altering the body's hormonal balance. The minoxidil vs finasteride guide explains the systemic approach topical antagonists are designed to avoid.

The Phase 3 Data, and Its Honest Caveats

Here is the verified data, along with the context that matters for reading it correctly.

Kintor announced that pyrilutamide met the primary endpoint in its pivotal Phase 3 trial for male androgenetic alopecia. The trial enrolled 666 patients across 26 centres, and both the 1.0% and 0.5% twice-daily formulations produced statistically significant improvements in target area hair count over placebo, with the 1.0% dose increasing hair count by 10.65 hairs per square centimetre more than placebo. A separate 52-week safety trial also passed.

Now the caveats. These are company-reported topline results, not yet a full peer-reviewed publication. The trial was conducted entirely in China with an all-Chinese patient population, raising reasonable questions about how directly the results translate to other ethnicities, though the underlying biology of androgenetic alopecia is broadly shared. And Kintor has been a recurring point of debate within the hair loss research community, a reason to hold these results as promising rather than definitive until independent publication confirms them.

None of this means the data is wrong. It means the right response is cautious optimism, pending verification.

Pyrilutamide vs Clascoterone: The First Real Race

Because pyrilutamide and clascoterone target the same receptor through the same mechanism, they are direct competitors, and the comparison is interesting.

Clascoterone (Breezula), from Cosmo Pharmaceuticals, reported positive Phase 3 data in December 2025 and is preparing parallel US and European submissions. Pyrilutamide took the Asian route first. In preclinical studies, pyrilutamide showed higher binding affinity to the androgen receptor than clascoterone, and Kintor has positioned it as a competitor aiming to be the first topical AR antagonist approved globally.

Two drugs, the same lock, the same mechanism. Clascoterone is racing through Western regulators, pyrilutamide through Asian ones. Whichever crosses first, the real winner is the finasteride-hesitant patient who finally gets a topical DHT blocker without systemic hormonal effects.

Higher binding affinity in a lab does not automatically translate to superior patient results, so the preclinical edge is a point of interest, not a proven advantage. What matters is that two credible drugs are advancing the same approach, increasing the odds at least one reaches wide availability.

When Will Pyrilutamide Be Available?

This is what most people searching for pyrilutamide want to know.

Kintor has stated it will file a New Drug Application with China's National Medical Products Administration following the Phase 3 result. If that proceeds smoothly, approval in China could come first, potentially around 2027, making China one of the earliest markets to have a topical AR antagonist for hair loss commercially available.

For the rest of the world, the picture is less certain. Kintor's announcements have focused on the Chinese filing, with no confirmed timeline for US or European submissions. Pyrilutamide is not approved by the FDA or any Western regulator, and its studies are still listed as ongoing. Western approval, if pursued, would be years away, and Pakistan access well beyond that.

A direct warning: pyrilutamide is easy to find for sale online, often from unregulated sources marketing research chemicals. Buying an unapproved drug this way carries real risks around purity, dosing, and safety, with no regulatory protection. Until it is properly approved through legitimate channels, it is not a safe purchase.

What This Means If You Are Losing Hair Now

Pyrilutamide is one of the more advanced drugs in the pipeline, and for people in China it may become available relatively soon. For everyone else, including Pakistan, it remains a future prospect. Waiting is not a workable plan: every month of untreated hair loss allows more follicles to miniaturise, and proven treatments work best started early.

For active hair loss now, the proven standard is minoxidil plus finasteride in the hair fall solution range at verified concentrations. For those drawn to pyrilutamide out of fear of finasteride's systemic effects, the practical near-term answer is topical finasteride, which already reduces systemic exposure substantially, as covered in the topical vs oral finasteride guide. The full hair care range supports preserving follicles now, so they remain healthy for whatever arrives next.

Frequently Asked Questions

What is pyrilutamide? Pyrilutamide, also called KX-826, is an investigational topical androgen receptor antagonist for hair loss, developed by Kintor Pharmaceutical in China. It blocks DHT at the scalp receptor without lowering DHT throughout the body, the same mechanism as clascoterone.

Is pyrilutamide FDA approved? No. Pyrilutamide is not approved by the FDA or any other regulator. Kintor is filing for approval in China first, with no announced US or European submission. Studies are still listed as in clinical trial phase.

When will pyrilutamide be available? Approval in China could come first, potentially around 2027. Western availability, if pursued, would be years further out, and Pakistan later still. It is not legitimately available anywhere today.

Kya pyrilutamide Pakistan mein milta hai? Nahi. Pyrilutamide abhi kisi bhi regulator se approved nahi hai. Pehle China mein approval mumkin hai, shayad 2027 ke qareeb. Pakistan tak pahunchne mein kaafi saal lagenge. Online jo "research chemical" ke tor par bikta hai woh unregulated aur ghair-mehfooz hai. Filhaal proven treatment, jaise minoxidil aur finasteride, hi use karein.

Pyrilutamide clascoterone se behtar hai kya? Dono ek hi mechanism par kaam karte hain aur ek hi receptor ko target karte hain. Preclinical studies mein pyrilutamide ki binding affinity zyada thi, lekin lab ka natija hamesha patient mein behtar result nahi deta. Dono achhe candidates hain, aur asal faida yeh hai ke DHT ko systemic side effects ke baghair block karne wale options barh rahe hain.

To Sum Up

Pyrilutamide is a topical DHT blocker that works like clascoterone, and it has taken an unusual route: developed in China, cleared through Phase 3 there, heading for approval in Asia potentially before the West. Its 666-patient trial met its endpoint, with the 1.0% dose adding 10.65 hairs per square centimetre over placebo, though the data remains company-reported, all-Chinese, and awaiting independent verification.

For people in China it may arrive relatively soon. For Pakistan and most of the world it is a future option, and versions sold online today are unregulated and unsafe. The encouraging picture is that two credible topical AR antagonists are now racing toward approval, improving the odds that the finasteride-hesitant will soon have a proven alternative. Until then, the treatment that helps you this year is the proven one that already exists, used consistently, starting now.

Hair Fall Solution Collection | Full Hair Care Range | Topical vs Oral Finasteride Guide